+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Centronuclear Myopathy Market by CNM Type (Adult-Onset, Pediatric), Diagnosis Method (Electromyography (EMG), Genetic Testing, Muscle Biopsy), Treatment Type, End-user - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967873
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Centronuclear Myopathy Market grew from USD 223.99 million in 2023 to USD 236.19 million in 2024. It is expected to continue growing at a CAGR of 5.71%, reaching USD 330.58 million by 2030.

Developments in gene therapy and molecular medicine provide potential breakthrough treatments for centronuclear myopathy (CNM). Greater recognition of CNM symptoms and ramifications by healthcare providers may lead to earlier diagnosis and treatment, improving patient outcomes. However, gaining approval for new treatments can be a lengthy and uncertain process, delaying market entry for new companies. The limited patient population of centronuclear myopathy restricts the market size, potentially reducing profitability and investment in research. Moreover, emerging markets present new opportunities for the application of advanced CNM treatments due to the growing healthcare infrastructure. Stronger patient advocacy initiatives may lead to increased funding for research and better policy support for affected individuals, creating opportunities for market expansion.

Regional Insights

In the Americas, major countries such as the United States and Canada have heightened awareness and diagnosis of rare diseases, including Centronuclear Myopathy (CNM), due to strong healthcare systems and comprehensive genetic testing practices. Healthcare policies in American countries often incorporate support for rare disease patients, including funding for medical care and research. EU countries exhibit a robust framework for rare disease management, characterized by the Orphan Medicinal Products Regulation, which facilitates developing and commercializing treatments for rare diseases. Consumer needs in the EU largely focus on integrating healthcare services and accessibility to treatment across different member states. The awareness and treatment of rare diseases, including centronuclear myopathy, in the Middle East and Africa are emerging gradually due to increasing investments in healthcare infrastructure. However, Africa faces challenges due to limited resources and non-governmental organizations often spearhead initiatives and international partnerships focused on improving healthcare capabilities. In Asia Pacific, countries including Japan and China are leading in terms of research and development related to rare diseases. Japan has established policies for fostering the development of rare disease treatment, heavily influencing customer purchasing towards highly specialized medical care and novel therapies. China is rapidly expanding its genetic research capabilities and has introduced policies to enhance the diagnosis and treatment of rare diseases, including centronuclear myopathy. India is progressively recognizing the importance of tackling rare diseases, with the government initiatives focused on both providing affordable treatments and improving diagnostic services.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Centronuclear Myopathy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Increasing prevalence and awareness of centronuclear myopathy
  • Governments and regulatory bodies support treatments for rare diseases

Market Restraints

  • Incidents of product recall due to unforeseen side effects or non-compliance with regulatory standards

Market Opportunities

  • Advancements in genetic research and diagnostic technologies
  • Awareness campaigns and increasing availability of treatment through partnership

Market Challenges

  • Complexities in drug development and manufacturing

Market Segmentation Analysis

  • CNM Type: Understanding centronuclear myopathy and pediatric cases for improved management and quality of life
  • End-user: Advancing role of hospitals in diagnosis, treatment, and management

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Centronuclear Myopathy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Centronuclear Myopathy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Astellas Pharma and Kate Therapeutics Forge Partnership for Advancement of Pioneering Gene Therapy for X-Linked Myotubular Myopathy

Astellas Pharma Inc., in partnership with Kate Therapeutics, announced an exclusive licensing deal to develop and market KT430, an innovative gene therapy aimed at treating X-linked myotubular myopathy (XLMTM). Under the partnership, Astellas is planned to handle the worldwide development, manufacturing, and commercialization rights to KT430, and will compensate KateTx with an upfront payment and potential further payments tied to developmental, regulatory, and commercial milestones, along with royalties on global sales.

FDA Accelerates Dynacure’s DYN101 Development for Centronuclear Myopathy Treatment

Dynacure, a biotechnology firm focused on rare genetic disorders, has announced the receipt of Fast Track Designation from the U.S. FDA for DYN101, its principal candidate targeted at treating Centronuclear Myopathy (CNM), including X-linked myotubular myopathy and autosomal dominant CNM. This designation is intended to hasten the development and review process of treatments for serious health conditions lacking effective medical solutions. This FDA recognition underscores the critical need for new therapies in addressing the severe impacts of CNM.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Centronuclear Myopathy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Centronuclear Myopathy Market, highlighting leading vendors and their innovative profiles. These include ARMGO Pharma, Inc., Audentes Therapeutics, CENTOGENE N.V., Cipla Ltd., Dynacure by Flamingo Therapeutics, FDC Ltd., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi, and Stealth BioTherapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Centronuclear Myopathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

CNM Type

  • Adult-Onset
  • Pediatric

Diagnosis Method

  • Electromyography (EMG)
  • Genetic Testing
  • Muscle Biopsy

Treatment Type

  • Medications
  • Physical Therapy

End-user

  • Hospitals
  • Research Institutions
  • Specialty Clinics

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence and awareness of centronuclear myopathy
5.1.1.2. Governments and regulatory bodies support treatments for rare diseases
5.1.2. Restraints
5.1.2.1. Incidents of product recall due to unforeseen side effects or non-compliance with regulatory standards
5.1.3. Opportunities
5.1.3.1. Advancements in genetic research and diagnostic technologies
5.1.3.2. Awareness campaigns and increasing availability of treatment through partnership
5.1.4. Challenges
5.1.4.1. Complexities in drug development and manufacturing
5.2. Market Segmentation Analysis
5.2.1. CNM Type: Understanding centronuclear myopathy and pediatric cases for improved management and quality of life
5.2.2. End-user: Advancing role of hospitals in diagnosis, treatment, and management
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Centronuclear Myopathy Market, by CNM Type
6.1. Introduction
6.2. Adult-Onset
6.3. Pediatric
7. Centronuclear Myopathy Market, by Diagnosis Method
7.1. Introduction
7.2. Electromyography (EMG)
7.3. Genetic Testing
7.4. Muscle Biopsy
8. Centronuclear Myopathy Market, by Treatment Type
8.1. Introduction
8.2. Medications
8.3. Physical Therapy
9. Centronuclear Myopathy Market, by End-user
9.1. Introduction
9.2. Hospitals
9.3. Research Institutions
9.4. Specialty Clinics
10. Americas Centronuclear Myopathy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Centronuclear Myopathy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Centronuclear Myopathy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Astellas Pharma and Kate Therapeutics Forge Partnership for Advancement of Pioneering Gene Therapy for X-Linked Myotubular Myopathy
13.3.2. FDA Accelerates Dynacure’s DYN101 Development for Centronuclear Myopathy Treatment
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. CENTRONUCLEAR MYOPATHY MARKET RESEARCH PROCESS
FIGURE 2. CENTRONUCLEAR MYOPATHY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CENTRONUCLEAR MYOPATHY MARKET DYNAMICS
FIGURE 7. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CENTRONUCLEAR MYOPATHY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. CENTRONUCLEAR MYOPATHY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CENTRONUCLEAR MYOPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY ADULT-ONSET, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY ADULT-ONSET, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY ELECTROMYOGRAPHY (EMG), BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY ELECTROMYOGRAPHY (EMG), BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY MUSCLE BIOPSY, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY MUSCLE BIOPSY, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 45. ARGENTINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 46. ARGENTINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 49. ARGENTINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 50. ARGENTINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 51. ARGENTINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 52. ARGENTINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 53. BRAZIL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 54. BRAZIL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 55. BRAZIL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 56. BRAZIL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 57. BRAZIL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 58. BRAZIL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 59. BRAZIL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 60. BRAZIL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 61. CANADA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 62. CANADA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 63. CANADA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 64. CANADA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 65. CANADA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 66. CANADA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 67. CANADA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 68. CANADA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 69. MEXICO CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 70. MEXICO CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 71. MEXICO CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 72. MEXICO CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 73. MEXICO CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 74. MEXICO CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 75. MEXICO CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 76. MEXICO CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 77. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 78. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 79. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 80. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 81. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 82. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 83. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 84. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 85. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 86. UNITED STATES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 88. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 90. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 92. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 94. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 96. ASIA-PACIFIC CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 97. AUSTRALIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 98. AUSTRALIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 99. AUSTRALIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 100. AUSTRALIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 101. AUSTRALIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 102. AUSTRALIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 103. AUSTRALIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 104. AUSTRALIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 105. CHINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 106. CHINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 107. CHINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 108. CHINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 109. CHINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 110. CHINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 111. CHINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 112. CHINA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 113. INDIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 114. INDIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 115. INDIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 116. INDIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 117. INDIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 118. INDIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 119. INDIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 120. INDIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 121. INDONESIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 122. INDONESIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 123. INDONESIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 124. INDONESIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 125. INDONESIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 126. INDONESIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 127. INDONESIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 128. INDONESIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 129. JAPAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 130. JAPAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 131. JAPAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 132. JAPAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 133. JAPAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 134. JAPAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 135. JAPAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 136. JAPAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 137. MALAYSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 138. MALAYSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 139. MALAYSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 140. MALAYSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 141. MALAYSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 142. MALAYSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 143. MALAYSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 144. MALAYSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 145. PHILIPPINES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 146. PHILIPPINES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 147. PHILIPPINES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 148. PHILIPPINES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 149. PHILIPPINES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 150. PHILIPPINES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 151. PHILIPPINES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 152. PHILIPPINES CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 153. SINGAPORE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 154. SINGAPORE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 155. SINGAPORE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 156. SINGAPORE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 157. SINGAPORE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 158. SINGAPORE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 159. SINGAPORE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 160. SINGAPORE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 161. SOUTH KOREA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 162. SOUTH KOREA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 163. SOUTH KOREA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 164. SOUTH KOREA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 165. SOUTH KOREA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 166. SOUTH KOREA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 167. SOUTH KOREA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 168. SOUTH KOREA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 169. TAIWAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 170. TAIWAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 171. TAIWAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 172. TAIWAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 173. TAIWAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 174. TAIWAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 175. TAIWAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 176. TAIWAN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 177. THAILAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 178. THAILAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 179. THAILAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 180. THAILAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 181. THAILAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 182. THAILAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 183. THAILAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 184. THAILAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 185. VIETNAM CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 186. VIETNAM CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 187. VIETNAM CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 188. VIETNAM CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 189. VIETNAM CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 190. VIETNAM CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 191. VIETNAM CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 192. VIETNAM CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 203. DENMARK CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 204. DENMARK CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 205. DENMARK CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 206. DENMARK CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 207. DENMARK CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 208. DENMARK CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 209. DENMARK CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 210. DENMARK CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 211. EGYPT CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 212. EGYPT CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 213. EGYPT CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 214. EGYPT CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 215. EGYPT CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 216. EGYPT CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 217. EGYPT CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 218. EGYPT CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 219. FINLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 220. FINLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 221. FINLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 222. FINLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 223. FINLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 224. FINLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 225. FINLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 226. FINLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 227. FRANCE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 228. FRANCE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 229. FRANCE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 230. FRANCE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 231. FRANCE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 232. FRANCE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 233. FRANCE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 234. FRANCE CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 235. GERMANY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 236. GERMANY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 237. GERMANY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 238. GERMANY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 239. GERMANY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 240. GERMANY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 241. GERMANY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 242. GERMANY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 243. ISRAEL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 244. ISRAEL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 245. ISRAEL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 246. ISRAEL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 247. ISRAEL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 248. ISRAEL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 249. ISRAEL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 250. ISRAEL CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 251. ITALY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 252. ITALY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 253. ITALY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 254. ITALY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 255. ITALY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 256. ITALY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 257. ITALY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 258. ITALY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 259. NETHERLANDS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 260. NETHERLANDS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 261. NETHERLANDS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 262. NETHERLANDS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 263. NETHERLANDS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 264. NETHERLANDS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 265. NETHERLANDS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 266. NETHERLANDS CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 267. NIGERIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 268. NIGERIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 269. NIGERIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 270. NIGERIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 271. NIGERIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 272. NIGERIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 273. NIGERIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 274. NIGERIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 275. NORWAY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 276. NORWAY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 277. NORWAY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 278. NORWAY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 279. NORWAY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 280. NORWAY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 281. NORWAY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 282. NORWAY CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 283. POLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 284. POLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 285. POLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 286. POLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 287. POLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 288. POLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 289. POLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 290. POLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 291. QATAR CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 292. QATAR CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 293. QATAR CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 294. QATAR CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 295. QATAR CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 296. QATAR CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 297. QATAR CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 298. QATAR CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 299. RUSSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 300. RUSSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 301. RUSSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 302. RUSSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 303. RUSSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 304. RUSSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 305. RUSSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 306. RUSSIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 308. SAUDI ARABIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 310. SAUDI ARABIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 312. SAUDI ARABIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 314. SAUDI ARABIA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 316. SOUTH AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 318. SOUTH AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 320. SOUTH AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 322. SOUTH AFRICA CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 323. SPAIN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 324. SPAIN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 325. SPAIN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 326. SPAIN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 327. SPAIN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 328. SPAIN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 329. SPAIN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 330. SPAIN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 331. SWEDEN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 332. SWEDEN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2024-2030 (USD MILLION)
TABLE 333. SWEDEN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2023 (USD MILLION)
TABLE 334. SWEDEN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2024-2030 (USD MILLION)
TABLE 335. SWEDEN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 336. SWEDEN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 337. SWEDEN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 338. SWEDEN CENTRONUCLEAR MYOPATHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 339. SWITZERLAND CENTRONUCLEAR MYOPATHY MARKET SIZE, BY CNM TYPE, 2018-2023 (USD MILLION)
TABLE 340.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ARMGO Pharma, Inc.
  • Audentes Therapeutics
  • CENTOGENE N.V.
  • Cipla Ltd.
  • Dynacure by Flamingo Therapeutics
  • FDC Ltd.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stealth BioTherapeutics Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 236.19 Million
Forecasted Market Value ( USD ) by 2030 $ 330.58 Million
Compound Annual Growth Rate5.7%
Regions CoveredGlobal

Related Topics

Related Reports

Centronuclear Myopathy - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Centronuclear Myopathy - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Centronuclear Myopathy - Pipeline Insight, 2024 - Product Image

Centronuclear Myopathy - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Mitochondrial Myopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Mitochondrial Myopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 134 Pages
  • Global
From
Mitochondrial Myopathy Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Mitochondrial Myopathy Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 84 Pages
  • Global
From
Global Cerebral Adrenoleukodystrophy Market by Type (Diagnosis, Treatment), End-User (Home Care Services, Hospitals & Clinical, Specialty Clinics) - Forecast 2024-2030 - Product Image

Global Cerebral Adrenoleukodystrophy Market by Type (Diagnosis, Treatment), End-User (Home Care Services, Hospitals & Clinical, Specialty Clinics) - Forecast 2024-2030

  • Report
  • 181 Pages
  • Global
From

About the Centronuclear Myopathy Drug Market

Centronuclear myopathy (CNM) is a rare, inherited neuromuscular disorder that affects the skeletal muscles. It is caused by mutations in genes that are involved in the development and maintenance of muscle fibers. Treatment for CNM is limited and typically involves physical therapy, occupational therapy, and supportive care. The Centronuclear Myopathy Drug market is a subset of the Central Nervous System Drugs market. It is a small but growing market, with a focus on developing treatments for CNM. Currently, there are no approved drugs for the treatment of CNM, but several companies are researching and developing potential therapies. These therapies include gene therapy, small molecule drugs, and stem cell therapy. Some companies in the Centronuclear Myopathy Drug market include Pfizer, Novartis, Sanofi, and Biogen. These companies are researching and developing potential therapies for CNM, with the goal of providing effective treatments for this rare disorder. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.